Experimental Ebola antibody protects monkeys

February 25, 2016, NIH/National Institute of Allergy and Infectious Diseases
The Ebola virus surface glycoprotein (blue) is shown bound by protective antibodies mAb114 (pink/white) and mAb100 (purple/white). Credit: NIAID

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleagues have discovered that a single monoclonal antibody—a protein that attacks viruses—isolated from a human Ebola virus disease survivor protected non-human primates when given as late as five days after lethal Ebola infection. The antibody can now advance to testing in humans as a potential treatment for Ebola virus disease. There are currently no licensed treatments for Ebola infection, which caused more than 11,000 deaths in the 2014-2015 outbreak in West Africa. The findings are described in two articles to be published online by Science on February 25.

NIAID researchers obtained and tested blood samples from a survivor of the 1995 Ebola outbreak in Kikwit, Democratic Republic of the Congo, and discovered the survivor retained antibodies against Ebola. Investigators from the Institute for Research in Biomedicine in Switzerland then isolated specific antibodies for potential use as a therapeutic for Ebola infection. Investigators from the United States Army Medical Research Institute of Infectious Diseases administered a lethal dose of Zaire ebolavirus to four rhesus macaques, waited five days, and then treated three of the macaques with daily intravenous injections of the monoclonal antibody, known as mAb114, for three consecutive days. The untreated control macaque showed indicators of Ebola virus disease and died on day nine, but the treatment group survived and remained free of Ebola symptoms.

NIAID and Dartmouth College researchers then studied how mAb114 neutralizes the Ebola virus and determined that it binds to the core of the Ebola glycoprotein, blocking its interaction with a receptor on human cells. This area of the Ebola glycoprotein, called the receptor binding domain, was previously thought to be unreachable by antibodies because it is well-hidden by other parts of the virus, and only becomes exposed after the virus enters the inside of cells. This is the first antibody to demonstrate the ability to neutralize the virus by this interaction between the virus and its cellular receptor. Together the evidence identifies a novel site of vulnerability on the Ebola virus and suggests mAb114 could be an effective therapy and warrants further exploration, according to the authors.

Explore further: Experimental immunotherapy zaps two most lethal Ebola virus strains

More information: D Corti et al. Protective Monotherapy Against Lethal Ebola Virus Infection by a Potent Neutralizing Antibody. Science DOI: 10.1126/science.aad5224 (2016)

J Misasi et al. Structural and Molecular Basis for Ebola Virus Neutralization by Protective Human Antibodies. Science DOI: 10.1126/science.aad6117 (2016)

Related Stories

Experimental immunotherapy zaps two most lethal Ebola virus strains

January 13, 2016
Researchers at Albert Einstein College of Medicine and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) have engineered the first antibodies that can potently neutralize the two deadliest strains ...

Researchers discover new Ebola-fighting antibodies in blood of outbreak survivor (Update)

February 18, 2016
A research team that included scientists from The Scripps Research Institute (TSRI) has identified a new group of powerful antibodies to fight Ebola virus.

New study highlights effectiveness of a herpesvirus CMV-based vaccine against Ebola

February 15, 2016
As the latest in a series of studies, researchers at Plymouth University, National Institutes of Health and University of California, Riverside, have shown the ability of a vaccine vector based on a common herpesvirus called ...

Experimental Ebola vaccines well tolerated, immunogenic in phase 2 study

February 24, 2016
Two investigational vaccines designed to protect against Ebola virus disease were well-tolerated and induced an immune response among 1,000 vaccinated participants in the Phase 2 randomized, placebo-controlled clinical trial ...

Antibodies may provide 'silver bullet' for Ebola viruses

January 21, 2016
There may be a "silver bullet" for Ebola, a family of hemorrhagic viruses, one of which has killed more than 11,000 people in West Africa in the past two years.

Study: Experimental Ebola drug ZMapp may benefit patients, but insufficient data

February 24, 2016
According to initial results from a randomized, controlled trial of the experimental Ebola treatment ZMapp, the monoclonal antibody cocktail was well-tolerated and showed promise. Due to decreasing incidence in Ebola, the ...

Recommended for you

Study reveals how kidney disease happens

February 22, 2018
Monash researchers have solved a mystery, revealing how certain immune cells work together to instigate autoimmune kidney disease.

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

Flu shot only 36 percent effective, making bad year worse (Update)

February 15, 2018
The flu vaccine is doing a poor job protecting older Americans and others against the bug that's causing most illnesses.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.